世界病毒学杂志(英文版)最新文献

{"title":"Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.","authors":"Nermin Kamal Saeed, Safiya Almusawi, Mohammed Al-Beltagi","doi":"10.5501/wjv.v13.i4.98839","DOIUrl":"10.5501/wjv.v13.i4.98839","url":null,"abstract":"<p><strong>Background: </strong>Invasive fungal infections, particularly candidemia, pose significant clinical challenges globally. Understanding local epidemiology, species distribution, and antifungal susceptibility patterns is crucial for effective management despite regional variations.</p><p><strong>Aim: </strong>To investigate the epidemiology, species distribution, antifungal susceptibility patterns, and associated risk factors of candidemia among patients in Bahrain from 2021 to 2023.</p><p><strong>Methods: </strong>This retrospective study analyzed demographic data, <i>Candida</i> species distribution, antifungal susceptibility profiles, and risk factors among candidemia patients treated at a tertiary care hospital in Bahrain over three years. Data was collected from medical records and analyzed using descriptive statistics.</p><p><strong>Results: </strong>A total of 430 candidemia cases were identified. The mean age of patients was 65.7 years, with a mortality rate of 85.5%. <i>Candida albicans</i> (<i>C. albicans</i>) was the most common species, followed by <i>Candida parapsilosis</i>, <i>Candida tropicalis (C. tropicalis)</i>, and emerging multidrug-resistant <i>Candida auris</i> (<i>C. auris</i>). Antifungal susceptibility varied across species, with declining susceptibility to azoles observed, particularly among <i>C. albicans</i> and <i>C. tropicalis</i>. Major risk factors included central venous catheters, broad-spectrum antibiotics, and surgical procedures.</p><p><strong>Conclusion: </strong>This study highlights the substantial burden of candidemia among older adults in Bahrain, characterized by diverse <i>Candida</i> species. It also concerns levels of antifungal resistance, notably in <i>C. auris</i>. The findings underscore the importance of local epidemiological surveillance and tailored treatment strategies to improve outcomes and mitigate the spread of multidrug-resistant <i>Candida</i> species. Future research should focus on molecular resistance mechanisms and optimizing therapeutic approaches to address this growing public health concern.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 4","pages":"98839"},"PeriodicalIF":0.0,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights from respiratory virus co-infections.","authors":"Vasiliki E Georgakopoulou","doi":"10.5501/wjv.v13.i4.98600","DOIUrl":"10.5501/wjv.v13.i4.98600","url":null,"abstract":"<p><p>Respiratory viral co-infections present significant challenges in clinical settings due to their impact on disease severity and patient outcomes. Current diagnostic methods often miss these co-infections, complicating the epidemiology and management of these cases. Research, primarily conducted <i>in vitro</i> and <i>in vivo</i>, suggests that co-infections can lead to more severe illnesses, increased hospitalization rates, and greater healthcare utilization, especially in high-risk groups such as children, the elderly, and immunocompromised individuals. Common co-infection patterns, risk factors, and their impact on disease dynamics highlight the need for advanced diagnostic techniques and tailored therapeutic strategies. Understanding the virological interactions and immune response modulation during co-infections is crucial for developing effective public health interventions and improving patient outcomes. Future research should focus on the molecular mechanisms of co-infection and the development of specific therapies to mitigate the adverse effects of these complex infections.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 4","pages":"98600"},"PeriodicalIF":0.0,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of vitamin D on COVID-19 and other viral diseases.","authors":"Basavraj S Nagoba, Ajay M Gavkare, Abhijit S Rayate, Neeta Nanaware, Sachin Bhavthankar","doi":"10.5501/wjv.v13.i4.100356","DOIUrl":"10.5501/wjv.v13.i4.100356","url":null,"abstract":"<p><p>This editorial aims to elucidate the intricate relationship between vitamin D and viral pathogenesis. It explores the anticipated role of vitamin D as a modulator in the immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other viral pathogens. The editorial comments are based on the review article by Engin <i>et al</i>. The potential role of vitamin D in modulating immune responses has been highlighted by several studies, suggesting that it may influence both the risk and severity of infections. Vitamin D receptors are present in immunocompetent cells, which indicates that vitamin D can potentially modulate innate and adaptive immune responses. This context is relevant in the pathophysiology of coronavirus disease 2019 (COVID-19), where the immune response to the virus can significantly impact the disease progression and outcome. The immunomodulatory effects of vitamin D can protect against SARS-CoV-2 infection by enhancing innate and adaptive immune responses. It also maintains the integrity of the body's physical barriers and modulates inflammatory responses, thereby preventing entry and replication of the virus. Many studies have suggested that adequate vitamin D levels help alleviate morbidity and mortality associated with COVID-19. Furthermore, vitamin D supplementation has been linked with a lower risk of severe disease and mortality in COVID-19 patients, particularly in those with a deficiency during seasons with less sunlight exposure.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 4","pages":"100356"},"PeriodicalIF":0.0,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142900841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant-based vaccines against viral hepatitis: A panoptic review.","authors":"Devanathan Reka, Chandrashekaran Girish","doi":"10.5501/wjv.v13.i3.97162","DOIUrl":"https://doi.org/10.5501/wjv.v13.i3.97162","url":null,"abstract":"<p><p>The traditional vaccines against hepatitis have been instrumental in reducing the incidence of some types of viral hepatitis; however, the need for cost-effective, easily distributable, and needle-free vaccine alternatives has led to the exploration of plant-based vaccines. Plant-based techniques offer a promising avenue for producing viral hepatitis vaccines due to their low-cost cultivation, scalability, and the potential for oral administration. This review highlights the successful expression of hepatitis B surface antigens in plants and the subsequent formation of virus-like particles, which have shown immunogenicity in preclinical and clinical trials. The challenges such as achieving sufficient antigen expression levels, ensuring consistent dosing, and navigating regulatory frameworks, are addressed. The review considers the potential of plant-based vaccines to meet the demands of rapid vaccine deployment in response to outbreaks and their role in global immunization strategies, particularly in resource-limited settings. This review underscores the significant strides made in plant molecular farming and the potential of plant-based vaccines to complement existing immunization methods against viral hepatitis.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 3","pages":"97162"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhabdomyolysis-related acute kidney injury in patients with COVID-19.","authors":"Ahmet Murt, Mehmet Riza Altiparmak","doi":"10.5501/wjv.v13.i3.91107","DOIUrl":"https://doi.org/10.5501/wjv.v13.i3.91107","url":null,"abstract":"<p><strong>Background: </strong>Viral and bacterial infections may be complicated by rhabdomyolysis, which has a spectrum of clinical presentations ranging from asymptomatic laboratory abnormalities to life-threatening conditions such as renal failure. Direct viral injury as well as inflammatory responses may cause rhabdomyolysis in the course of coronavirus disease 2019 (COVID-19). When presented with acute kidney injury (AKI), rhabdomyolysis may be related to higher morbidity and mortality.</p><p><strong>Aim: </strong>To compare rhabdomyolysis-related AKI with other AKIs during COVID-19.</p><p><strong>Methods: </strong>A total of 115 patients with COVID-19 who had AKI were evaluated retrospectively. Fifteen patients had a definite diagnosis of rhabdomyolysis (<i>i.e.</i>, creatine kinase levels increased to > 5 times the upper normal range with a concomitant increase in transaminases and lactate dehydrogenase). These patients were aged 61.0 ± 19.1 years and their baseline creatinine levels were 0.87 ± 0.13 mg/dL. Patients were treated according to national COVID-19 treatment guidelines. They were compared with patients with COVID-19 who had AKI due to other reasons.</p><p><strong>Results: </strong>For patients with rhabdomyolysis, creatinine reached 2.47 ± 1.17 mg/dL during follow-up in hospital. Of these patients, 13.3% had AKI upon hospital admission, and 86.4% developed AKI during hospital follow-up. Their peak C-reactive protein reached as high as 253.2 ± 80.6 mg/L and was higher than in patients with AKI due to other reasons (<i>P</i> < 0.01). Peak ferritin and procalcitonin levels were also higher for patients with rhabdomyolysis (<i>P</i> = 0.02 and <i>P</i> = 0.002, respectively). The mortality of patients with rhabdomyolysis was calculated as 73.3%, which was higher than in other patients with AKI (18.1%) (<i>P</i> = 0.001).</p><p><strong>Conclusion: </strong>Rhabdomyolysis was present in 13.0% of the patients who had AKI during COVID-19 infection. Rhabdomyolysis-related AKI is more proinflammatory and has a more mortal clinical course.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 3","pages":"91107"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ambispective epidemiological observational study of varicella-zoster virus infection: An 18 year-single-center Bulgarian experience.","authors":"Hristiana M Batselova, Tsvetelina V Velikova","doi":"10.5501/wjv.v13.i3.92525","DOIUrl":"https://doi.org/10.5501/wjv.v13.i3.92525","url":null,"abstract":"<p><strong>Background: </strong>Varicella (chickenpox) and herpes zoster (shingles) are outcomes of varicella-zoster virus (VZV) infection, and understanding their incidence trends is vital for public health planning.</p><p><strong>Aim: </strong>To conduct an ambispective epidemiological study by analyzing the main epidemiological characteristics of VZV infection during an 18 year-period (2000-2018).</p><p><strong>Methods: </strong>We used descriptive and epidemiological methods to characterize chickenpox in Bulgaria, the city of Plovdiv and the region for a period of 18 years (2000-2018).</p><p><strong>Results: </strong>The average incidence of varicella-zoster infection for the period 2000-2018 in the Plovdiv region was estimated at 449.58‰. The highest relative share of the infection was assessed in the month of January at 13.6%, and the lowest in the months of August and September at 2.9% (both months). The age group most affected by the infection was 1-4 years, followed by 5-9 years. This corresponds to the so-called \"pro-epidemic population\" - a phenomenon typical for airborne infections, confirming their mass impact on the perpetuation of VZV infection.</p><p><strong>Conclusion: </strong>Our findings reveal significant insights into VZV epidemiology, including age-specific incidence rates, clinical manifestations, and vaccination impact. This comprehensive analysis contributes to the broader understanding of VZV infection dynamics and may inform evidence-based preventive measures.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 3","pages":"92525"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral etiologies of acute liver failure.","authors":"Brian W McSteen, Xiao-Han Ying, Catherine Lucero, Arun B Jesudian","doi":"10.5501/wjv.v13.i3.97973","DOIUrl":"https://doi.org/10.5501/wjv.v13.i3.97973","url":null,"abstract":"<p><p>Acute liver failure (ALF) is a rare cause of liver-related mortality worldwide, with an estimated annual global incidence of more than one million cases. While drug-induced liver injury, including acetaminophen toxicity, is the leading cause of ALF in the Western world, viral infections remain a significant cause of ALF and the most common cause in many developing nations. Given the high mortality rates associated with ALF, healthcare providers should be aware of the broad range of viral infections that have been implicated to enable early diagnosis, rapid treatment initiation when possible, and optimal management, which may include liver transplantation. This review aims to provide a summary of viral causes of ALF, diagnostic approaches, treatment options, and expected outcomes.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 3","pages":"97973"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective study evaluating association of colorectal tumors and hepatitis C virus.","authors":"Maya Gogtay, Lekha Yadukumar, Yuvaraj Singh, Mithil Gowda Suresh, Aakriti Soni, Anuroop Yekula, Asha Bullappa, George M Abraham","doi":"10.5501/wjv.v13.i3.92647","DOIUrl":"https://doi.org/10.5501/wjv.v13.i3.92647","url":null,"abstract":"<p><strong>Background: </strong>Chronic hepatitis C virus (HCV) has been associated with hepatic and extrahepatic malignancies. Limited studies have shown an association between colorectal adenomas and HCV populations.</p><p><strong>Aim: </strong>To study the prevalence of colorectal adenomas in patients with HCV compared to the general population and to evaluate if it is an independent risk factor for colorectal adenomas.</p><p><strong>Methods: </strong>Patients were divided into HCV and non-HCV based on their HCV RNA titers. Patients with alcoholic liver disease, hepatitis B infection, and inflammatory bowel disease were excluded. Continuous variables were analyzed using the Mann-Whitney <i>U</i> test, and categorical variables using <i>χ</i> ² with <i>P</i> < 0.05 were considered statistically significant. The significant covariates (independent variables) were matched in both groups by propensity score matching, followed by multivariate regression analysis.</p><p><strong>Results: </strong>Of the 415 patients screened, 109 HCV patients and 97 non-HCV patients with colonoscopy results were included in the study. HCV patients were older, had a smoking history, had less frequent aspirin use, and had a lower body mass index (BMI) (<i>P</i> < 0.05). The HCV cohort had a significantly increased number of patients with adenomas (adenoma detection rate of 53.2% <i>vs</i> 34%. <i>P</i> = 0.006). We performed a propensity-matched multivariate analysis where HCV infection was significantly associated with colorectal adenoma (OR: 2.070, <i>P</i> = 0.019).</p><p><strong>Conclusion: </strong>Our study shows a significantly higher rate of adenomas in HCV patients compared to the general population. Prospective studies would help determine if the increase in adenoma detection lowers the risk for colorectal cancer.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 3","pages":"92647"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosage and utilization of dexamethasone in the management of COVID-19: A critical review.","authors":"Imran Sethi, Asim Shaikh, Musa Sethi, Hira Khalid Chohan, Sheraz Younus, Syed A Khan, Salim Surani","doi":"10.5501/wjv.v13.i3.95709","DOIUrl":"https://doi.org/10.5501/wjv.v13.i3.95709","url":null,"abstract":"<p><strong>Background: </strong>The severe respiratory manifestations observed in severe coronavirus disease 2019 (COVID-19) cases are often associated with an excessive inflammatory response. Dexamethasone, a synthetic glucocorticoid, exerts its anti-inflammatory effects by inhibiting the transcription of pro-inflammatory genes and suppressing the activity of various immune cells. This mechanism has implications for mitigating the cytokine storm observed in severe COVID-19 cases. Early on in the pandemic, the Recovery Collaborative working group showed a mortality benefit of using dexamethasone in decreasing mortality in patients with COVID-19 requiring respiratory support. However, the optimal dosage of corticosteroids remains debatable. Several studies that compare different doses of dexamethasone in COVID-19 exist, but the results are conflicting.</p><p><strong>Aim: </strong>To review the latest evidence regarding dosage, safety, and efficacy of dexamethasone in severe COVID-19.</p><p><strong>Methods: </strong>We followed preferred reporting items for systematic reviews and meta-analysis guidelines. A detailed literature search was conducted across PubMed, Google Scholar, and Medline to include publications up to March 2024. Our keywords included \"COVID-19\" \"SARS-CoV-2\" \"dexamethasone\" \"corticosteroid\" \"steroid\" and \"glucocorticoid\"-along with their combinations. We employed the Cochrane Risk of Bias Tool and the Newcastle-Ottawa scale to evaluate the integrity and potential of bias in the included studies. A meta-analysis was conducted using a random-effects model, assessing pooled odds ratios and mean differences, with heterogeneity gauged by the <i>I</i> ² statistic and the <i>χ</i> ² tests.</p><p><strong>Results: </strong>No statistical differences were found in 28-day all-cause mortality [pooled odds ratio (OR) = 1.109, 95%CI: 0.918-1.340], 60-day all-cause mortality (OR = 0.873, 95%CI: 0.744-1.024; <i>I</i> ² = 47.29%), mean length of hospital stay (mean difference = -0.08 days, 95%CI: -0.001 to 0.161) and adverse events (OR = 0.877, 95%CI: 0.707-1.087).</p><p><strong>Conclusion: </strong>Differing doses of corticosteroids have no clinical implications on mortality, mean length of hospital stay, and adverse events in COVID-19 patients. Additional research is required in patients requiring invasive or non-invasive ventilation.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 3","pages":"95709"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transplacental transmission of dengue infection.","authors":"Leonel Eslatkin Aguilar Zambrano, Victor Manuel Vasquez Zevallos, Gita Vita Soraya, Lola Ayu Istifiani, Syafrizal Aji Pamungkas, Zulvikar Syambani Ulhaq","doi":"10.5501/wjv.v13.i3.91325","DOIUrl":"https://doi.org/10.5501/wjv.v13.i3.91325","url":null,"abstract":"<p><p>We specifically addressed the persistent challenge of dengue in endemic regions, highlighting the potential seriousness of dengue infection through vertical transmission. Vertical dengue transmission has been well documented, particularly in hyper-endemic regions, including Ecuador. Herein, we present a neonate diagnosed with congenital dengue and review similar cases from previously published reports. Although congenital dengue is commonly infected with severe serotypes of DENV (DENV-1 and DENV-2) infections, favorable outcomes are generally observed.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"13 3","pages":"91325"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11400998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}